NCT02948348 - Study to Nivolumab Following Preoperative Chemoradiotherapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

December 31, 2021

Study Completion Date

August 31, 2022

Conditions

Cancer of Rectum

Interventions

DRUG

Nivolumab

Capecitabine:Dose of 1650mg/m2,14days, Radiation:45Gy/25 fractions, Nivolumab :240mg on day1 of each cycle, Surgical therapy:The resection (LAR), intersphincteric resection (ISR), or abdominoperineal resection (APR).

DRUG

Ipilimumab

For only Cohort D,1 mg/kg at six-week intervals

Trial Locations (3)

Unknown

RECRUITING

National Cancer Center Hospital East, Kashiwa

RECRUITING

Hokkaido University, Sapporo

RECRUITING

Osaka National Hospital, Osaka